[go: up one dir, main page]

AU2001232785A1 - Methods for lowering uric acid levels - Google Patents

Methods for lowering uric acid levels

Info

Publication number
AU2001232785A1
AU2001232785A1 AU2001232785A AU3278501A AU2001232785A1 AU 2001232785 A1 AU2001232785 A1 AU 2001232785A1 AU 2001232785 A AU2001232785 A AU 2001232785A AU 3278501 A AU3278501 A AU 3278501A AU 2001232785 A1 AU2001232785 A1 AU 2001232785A1
Authority
AU
Australia
Prior art keywords
methods
uric acid
acid levels
lowering uric
lowering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232785A
Inventor
Marcelle Boyd
Dale Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Pharmaceutical Discovery Inc
Original Assignee
Institute for Pharmaceutical Discovery Inc
Institutes for Pharmaceutical Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Pharmaceutical Discovery Inc, Institutes for Pharmaceutical Discovery Inc filed Critical Institute for Pharmaceutical Discovery Inc
Publication of AU2001232785A1 publication Critical patent/AU2001232785A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001232785A 2000-01-14 2001-01-11 Methods for lowering uric acid levels Abandoned AU2001232785A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17627300P 2000-01-14 2000-01-14
US60176273 2000-01-14
PCT/US2001/001004 WO2001051489A2 (en) 2000-01-14 2001-01-11 Methods for lowering uric acid levels

Publications (1)

Publication Number Publication Date
AU2001232785A1 true AU2001232785A1 (en) 2001-07-24

Family

ID=22643694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232785A Abandoned AU2001232785A1 (en) 2000-01-14 2001-01-11 Methods for lowering uric acid levels

Country Status (3)

Country Link
US (1) US20010044437A1 (en)
AU (1) AU2001232785A1 (en)
WO (1) WO2001051489A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509990A (en) 2008-01-22 2011-03-31 オキサジェン リミテッド Compound having CRTH2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL21582A (en) * 1963-07-15 1968-08-22 Merck & Co Inc Compositions for the treatment of gout comprising a substituted 3-indolyl-carboxylic acid derivative
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors

Also Published As

Publication number Publication date
WO2001051489A3 (en) 2001-12-27
US20010044437A1 (en) 2001-11-22
WO2001051489A2 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
AU2002325538A1 (en) Nucleic acid amplification methods
AU2002314693A1 (en) Nucleic acid amplification method
AU2002245184A1 (en) Nucleic acid amplification
AU2001278783A1 (en) Method of amplifying nucleic acid
AU2002219136A1 (en) Method for stabilizing polyolefins
AU2001280167A1 (en) Novel propenohydroxamic acid derivatives
AU7494100A (en) Charge-modified nucleic acid terminators
AU2002316863A1 (en) Method for the preferential nucleic acid amplification of selected nucleic acid regions
AU2002350942A1 (en) Imidazolidineacetic acid derivatives
AU2001244671A1 (en) Quinolonecarboxylic acid derivative
AU2001232785A1 (en) Methods for lowering uric acid levels
PL364901A1 (en) Oxalic acid derivatives
AU2001237546A1 (en) Methods for characterizing polymorphisms
AU2002366435A1 (en) Nucleic acid amplification
AU2001237530A1 (en) Method
AU2001284047A1 (en) Butinol I esterase
AU2001296348A1 (en) Reuse determination for high level disinfectant
AU2001252390A1 (en) Nucleic acid immunization
AU2001293697A1 (en) N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives
AU2001241636A1 (en) Halotherapy method
AU2001244628A1 (en) Pyroligneous acid
AU2001280916A1 (en) Methods for identifying genomic deletions
AU2002213695A1 (en) Method of genomic analysis
AU2852100A (en) Methods of modulating uric acid levels
AU2001228527A1 (en) Oxazolethoxyphenylpropanoic acid derivative as niddm- medicament